Related Experiment Video
Updated: Jun 4, 2026
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
Published on: November 9, 2018
When will Alzheimer's disease be cured? A pharmaceutical perspective
1EMD Serono Research Institute, Cambridge, MA 02139, USA. matthew.townsend@emdserono.com
Abstract:
Alzheimer's disease (AD) continues to be one of most difficult human diseases to treat. The past 18 months have been a cruel reminder of the challenges of finding new and effective treatments. In 2010, several large Phase III clinical trials were terminated for lack of therapeutic efficacy. Concurrently, an NIH expert review panel was resigned to conclude that there was insufficient scientific evidence to recommend any treatment choices for slowing the progression of AD. Why has this disease proved so daunting? The answer is complex. To begin, it is still not clear whether AD is one disease with a single cause or multiple syndromes with common symptoms and/or a common pathology. Resolving this question is a prerequisite for forecasting whether to expect a 'magic bullet' therapy or only incremental progress in select patient populations. This review will explore some of the details of recent clinical trials and consider some of the lessons learned. As therapies approach clinical trials, it is essential to understand the expectations of regulatory agencies such as the FDA and EMA to obtain approval. Lastly, we will cover some of the essential gaps in our scientific understanding about the disease process and the impact this has on target validation. The hope of finding of a quick cure for AD without a complete understanding of the disease may have been too optimistic. However, a prudent review of the scientific evidence, a clear understanding of the expectations of regulators, and careful attention to patient needs may still lead to good therapies in the foreseeable future.
Insights
Finding effective Alzheimer's disease (AD) treatments is challenging due to the disease's complex nature. A better understanding of AD pathology and regulatory expectations is crucial for developing successful therapies.
Area of Science:
- Neuroscience
- Gerontology
- Pharmacology
Background:
- Alzheimer's disease (AD) presents significant therapeutic challenges, with recent Phase III trials failing to demonstrate efficacy.
- Current understanding is insufficient to recommend treatments for slowing AD progression, highlighting a critical knowledge gap.
Purpose of the Study:
- To review recent clinical trials and identify lessons learned in Alzheimer's disease (AD) drug development.
- To discuss the complexities of AD, including its potential as a single disease or multiple syndromes.
- To examine regulatory expectations from agencies like the FDA and EMA for therapy approval.
Main Methods:
- Review of terminated Phase III clinical trials for Alzheimer's disease (AD).
- Analysis of expert reviews and scientific literature regarding AD pathology and treatment.
- Examination of regulatory guidelines for drug approval in neurodegenerative diseases.
Main Results:
- Recent Alzheimer's disease (AD) clinical trials have largely failed, indicating a need for revised therapeutic strategies.
- Significant gaps persist in understanding the fundamental disease processes of AD, impacting target validation.
- Regulatory agency expectations for AD therapies require clear efficacy and safety data.
Conclusions:
- A 'magic bullet' cure for Alzheimer's disease (AD) is unlikely without a deeper understanding of its underlying causes.
- Progress in AD treatment requires a comprehensive approach, integrating scientific evidence, regulatory insights, and patient needs.
- Future therapeutic development must address the complexity of AD and the validation of drug targets.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:29Pharmacogenomics: Identification of New Drug Targets
01:23Alzheimer Disease ll: Pathophysiology